Early Biomarkers as Predictors of Nephrology Trial Trajectory
Chronic kidney disease (CKD) and other nephrology conditions are a major global health challenge. With rising prevalence and persistent unmet…
All articles by Miranda Mclaren
Miranda Mclaren
-
-
How gene therapies are changing the Qualified Person role in the EU
For organisations outside Europe, the role of the Qualified Person (QP) is often unfamiliar. In the EU and UK, however,…
-
Q&A: How 3PLs are navigating the latest pharma trends
Pharmaceutical third-party logistics (3PL) providers are moving beyond traditional warehousing into more holistic and strategic commercialization support. At the same…
-
The Ovarian Cancer Opportunity: Overcoming Complexity in Global Studies
Each year in the US, more than 21,000 women will receive a new diagnosis of ovarian cancer according to the…
-
Trends in Renal Research: Nephrology’s Shift to Focus and Precision
Nephrology has long been a difficult space for drug development: trials were slow, complex, high cost, and often unrewarding, constrained…
-
Tell us: Is hospital connectivity keeping up with the demands of modern care in 2026?
For years, healthcare organizations have focused on enabling clinical mobility by giving clinicians access to systems, communication tools, and patient…
-
Operational Lessons from Global Nephrology Trials
From novel drug targets for chronic kidney disease (CKD)[i] to advances in multifunctional drugs promising better efficacy, recent developments in…
-
The future of quality in CDMOs: The five-stage journey to an advanced Pharmaceutical Quality System (PQS)
In the first part of our Q&A with Grace Breen, SVP, Quality, Sharp, we explored valuable insights derived from her…
-
Four ways to build a secure and scalable CGT distribution network
CGTs offer potentially life-changing treatment for a broad spectrum of complex diseases, from genetic conditions to cancers. The pace of…
-
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers
Oncology drug development has shifted decisively towards precision immunotherapies, where biomarker-defined patient populations play a pivotal role. Immuno-oncology now represents…